Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PKI-166 is an oral inhibitor of EGF-R tyrosine kinase (IC50:0.7 nM) that is both effective and selective. PKI-166 can effectively inhibit the growth and metastasis of various human cancer cells including pancreatic cancer.
説明 | PKI-166 is an oral inhibitor of EGF-R tyrosine kinase (IC50:0.7 nM) that is both effective and selective. PKI-166 can effectively inhibit the growth and metastasis of various human cancer cells including pancreatic cancer. |
ターゲット&IC50 | EGFR tyrosine kinase:0.7 nM |
In vitro | PKI-166 (0–0.5 μM; 1 hour) pretreatment suppresses EGFR autophosphorylation in human pancreatic cancer cells. PKI-166 (0.03μ M; 6 days) increased the cytotoxicity mediated by gemcitabine.[1] |
In vivo | PKI-166 (100 mg/kg; p.o.; daily; day 7-day 35 after xenograft) suppresses the growth of pancreatic cancer.[1] |
分子量 | 330.38 |
分子式 | C20H18N4O |
CAS No. | 187724-61-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 27.5 mg/mL (83.23 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PKI-166 187724-61-4 Angiogenesis Tyrosine Kinase/Adaptors VEGFR PKI 166 PKI166 Inhibitor inhibitor inhibit